Details of the Drug Combinations

General Information of This Drug (ID: DMCVJ86)

• Drug Name: Clofarabine (DMCVJ86)
• Synonyms: CAFdA; CFB; Clofarabina; Clofarabinum; Clofarex; Clolar; Evoltra; Clofarabine [USAN]; Clolar (TN); Evoltra (TN); Clofarabine (USAN/INN); Clolar, Evoltra, Clofarabine; Cl-F-Ara-A; (2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol; 2-Chloro-9-(2-deoxy-2-fluoro-b-D-arabinofuranosyl)-9H-purin-6-amine; 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purin-6-amine; 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine; 2-Cl-2'-F-araA; 2-chloro-9-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)adenine; 3S211048

Indication

Acute lymphoblastic leukaemia; ICD 11: 2A85; Status: Approved [1]; Acute myelogenous leukaemia; ICD 11: 2A41; Status: Approved [2]; Langerhans cell histiocytosis; ICD 11: N.A.; Status: Approved [2]; Leukemia; ICD 11: N.A.; Status: Approved [2]; Myelodysplastic syndrome; ICD 11: 2A37; Status: Approved [1]; Plasma cell myeloma; ICD 11: 2A83.1; Status: Approved [2]; Classic Hodgkin lymphoma; ICD 11: N.A.; Status: Investigative [2]

• Therapeutic Class: Anticancer Agents
• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Clofarabine + Idarubicin	DCBYSKM	Idarubicin	Glioblastoma? (Cell Line: T98G)	[3]

16 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Clofarabine + Cytarabine	DC4OGYY	Cytarabine	Leukemia	[4]
Clofarabine + Cytarabine	DCHA10E	Cytarabine	Acute Myelogenous Leukemia	[5]
Clofarabine + Decitabine	DCULP6R	Decitabine	Myelodysplastic Syndrome	[6]
Clofarabine + Busulfan	DCVVZTZ	Busulfan	Acute Myeloid Leukemia	[7]
Clofarabine + Mycophenolate mofetil	DCHJ30J	Mycophenolate mofetil	Leukemia Lymphoblastic, Acute	[8]
Clofarabine + Idarubicin	DCJEYW1	Idarubicin	Leukemia	[9]
Clofarabine + Mitoxantrone	DCPIVXM	Mitoxantrone	Acute Lymphoblastic Leukemia	[10]
Cyclophosphamide + Clofarabine	DCJJ5CN	Cyclophosphamide	Burkitt's Lymphoma	[11]
Methotrexate + Clofarabine	DC26KNS	Methotrexate	Leukemia	[12]
Plerixafor + Clofarabine	DCF45XK	Plerixafor	Acute Myelogenous Leukemia	[13]
Clofarabine + Sirolimus	DCE284T	Sirolimus	Adult Acute Lymphoblastic Leukemia in Remission	[14]
Clofarabine + Mycophenolate mofetil	DC1GX0X	Mycophenolate mofetil	Acute Myeloid Leukemia	[15]
Clofarabine + Fludarabine	DC2J2YF	Fludarabine	Myeloid Malignancy	[16]
Clofarabine + Decitabine	DC949GI	Decitabine	Acute Myeloid Leukemia	[17]
Cyclophosphamide + Clofarabine	DCCBX4E	Cyclophosphamide	Acute Myeloid Leukemia	[18]
Clofarabine + Decitabine	DC3Q6RR	Decitabine	Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome	[19]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6802).
• [2] Clofarabine FDA Label
• [3] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [4] ClinicalTrials.gov (NCT00337168) S0530 Cytarabine and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
• [5] ClinicalTrials.gov (NCT00317642) A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I)
• [6] ClinicalTrials.gov (NCT00903760) Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS)
• [7] ClinicalTrials.gov (NCT01643668) Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation
• [8] ClinicalTrials.gov (NCT01041508) Clofarabine and Low Dose Total Body Irradiation as a Preparative Regimen for Stem Cell Transplant in Leukemia.
• [9] ClinicalTrials.gov (NCT00838240) Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia
• [10] ClinicalTrials.gov (NCT01842672) Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia
• [11] ClinicalTrials.gov (NCT00412243) Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients
• [12] ClinicalTrials.gov (NCT00372619) Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
• [13] ClinicalTrials.gov (NCT01160354) Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML)
• [14] ClinicalTrials.gov (NCT01885689) Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia
• [15] ClinicalTrials.gov (NCT01252667) Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant
• [16] ClinicalTrials.gov (NCT01596699) Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation
• [17] ClinicalTrials.gov (NCT00778375) Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
• [18] ClinicalTrials.gov (NCT01677949) Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute Leukemia
• [19] ClinicalTrials.gov (NCT02085408) Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia